ArticleArthritis research & therapy2025
Low-dose rituximab in lupus enteritis: a comparative study on its efficacy in modulating mucosal immunity and reducing inflammation.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Schizophrenia as a Disorder of Biological Barriers: A Narrative Review and Potential Interventions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLupus enteritis (LE) is a serious manifestation of systemic lupus erythematosus (SLE), yet optimal treatment strategies remain unclear. This study aimed to compare the efficacy of rituximab (RTX) plus glucocorticoids versus glucocorticoids combined with conventional immunosuppressants in patients with moderate-to-severe LE.
methodsWe retrospectively analyzed 36 patients with SLE-related intestinal involvement treated at our center between January 2015 and August 2024; sixteen received RTX plus glucocorticoids, and twenty received glucocorticoids with conventional immunosuppressants. Baseline characteristics, clinical features, abdominal CT findings, laboratory parameters (including serum and fecal IgA, IL-6, TNF-α, and IL-10), and disease activity scores (SLEDAI-2 K and BILAG-2004) were assessed. For fecal IgA analysis, age- and sex-matched healthy controls without relevant diseases or recent antibiotic/microbiota-modulating use were included. Treatment response and safety outcomes were compared over 6 months.
resultsBoth patient groups exhibited comparable baseline characteristics. Both treatment strategies led to significant improvements in clinical symptoms and imaging abnormalities-including bowel wall thickening, mesenteric effusion, comb sign, or target sign-with no significant differences observed between the groups. After six months of treatment, the median SLEDAI-2 K score in the rituximab (RTX) group decreased from 15 to 0 (p < 0.001), and the BILAG-2004 score decreased from 31.5 to 0 (p < 0.001). IL-6 levels in the RTX group also significantly declined from 26.57 ± 7.94 pg/mL to 4.15 ± 2.10 pg/mL (p < 0.01), with a greater reduction compared to the control group. Fecal IgA levels were higher in lupus enteritis patients than in healthy controls and decreased in both groups following treatment. Baseline IL-6 correlated with SLEDAI-2 K and BILAG-2004 scores, whereas fecal IgA was elevated in patients with mesenteric effusion but not associated with overall disease activity. At 6 months, remission was achieved in 93.8% of RTX-treated patients and 85% of controls (p = 0.418), with comparable safety profiles.
conclusionBoth RTX plus glucocorticoids and conventional immunosuppressants plus glucocorticoids are effective in inducing clinical and radiologic remission in LE. RTX may lead to faster improvement in certain serologic and inflammatory biomarkers. Larger studies with longer follow-up and stratification by systemic involvement are warranted to optimize individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.